Company Overview
Snapshot
Founded in August 2013 by Ofer Shalev and Rafael Hof, New Phase operates with 11–50 employees. The company has raised $35 million across three funding rounds. In June 2024, New Phase received FDA approval for clinical trials in the U.S. for its groundbreaking cancer treatment.
Business overview
New Phase is a Health Tech & Life Sciences company focused on developing breakthrough solutions in Oncology. The company's core technology is a Nanotechnology System designed to treat metastatic solid tumors by delivering thermal energy to malignant cells, causing cancer cell death via electromagnetic hyperthermia without harming healthy tissues. This technology, which can act as a stand-alone treatment, aims to prolong patient life by turning cancer into a manageable chronic ailment. New Phase serves the healthcare industry, particularly providers and pharmaceutical companies, with its Sarah Nanoparticles (SaNPs) and Electromagnetic Induction System (EIS).
Strategic signal
In June 2024, New Phase secured FDA approval for clinical trials in the U.S. for its novel cancer treatment. This milestone is a significant validation of the company's nanotechnology system, signaling strong regulatory confidence and opening a critical pathway for market expansion and further clinical development in a major healthcare market. For investors, this indicates a de-risking event and potential for accelerated growth and commercialization.
Log in to access full profile ›Company Intelligence Q&A
- What is New Phase's primary therapeutic focus?
- New Phase is focused on developing breakthrough solutions in Oncology, specifically targeting metastatic solid tumors using its Nanotechnology System.
- When did New Phase receive FDA approval for clinical trials in the U.S.?
- In June 2024, New Phase received FDA approval for clinical trials in the U.S. for its cancer treatment technology.
- What is the core technology developed by New Phase?
- New Phase has developed a Nanotechnology System that uses Sarah Nanoparticles (SaNPs) and an Electromagnetic Induction System (EIS) to deliver thermal energy to malignant cells, causing cancer cell death via electromagnetic hyperthermia.
- When did New Phase begin human trials for its technology?
- In March 2022, New Phase began human trials for its technology aimed at prolonging the lives of cancer patients.
- What was a key early development for New Phase's cancer treatment?
- In April 2016, New Phase successfully completed small mammal pre-clinical trials for a cancer treatment designed to transform cancer into a treatable chronic ailment.